In vivo studies support an anti-inflammatory role for Gal-1, and Santucci et. al. showed that prophylactic or therapeutic administration of Gal-1 can significantly reduce TNBS-induced colitis by preventing T cell activation and pro-inflammatory cytokine production[11]. This evidence concerns the gene LGALS1 and colitis.